Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020618 · ClinicalTrials.gov registry record · Phase 2
Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00020618 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute.
The verdict
NCT00020618, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Morphine that is inhaled may be more rapidly absorbed than morphine that is given by mouth. It is not yet known if inhaled morphine is more effective than morphine given by mouth in relieving breakthrough pain. PURPOSE: Randomized phase II trial to compare the effectiveness of inhaled morphine with that of morphine given by mouth in treating cancer patients who have breakthrough pain.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG morphine sulfate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-03 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020618
The ClinicalTrials.gov registry entry for NCT00020618 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00020618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020618 about?
NCT00020618 is a clinical study titled "Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain". RATIONALE: Morphine that is inhaled may be more rapidly absorbed than morphine that is given by mouth. It is not yet known if inhaled morphine is more effective than morphine given by mouth in relieving breakthrough pain. PURPOSE: Randomized phase II trial to compare the effectiveness of inhaled mo...
What is the current status of trial NCT00020618?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-03. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00020618?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), morphine sulfate (DRUG).
Who is sponsoring clinical trial NCT00020618?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.